Ross Jonathan, Murenzi Gad, Hill Sarah, Remera Eric, Ingabire Charles, Umwiza Francine, Munyaneza Athanase, Muhoza Benjamin, Habimana Dominique Savio, Mugwaneza Placidie, Zhang Chenshu, Yotebieng Marcel, Anastos Kathryn
Division of General Internal Medicine, Montefiore Health System, Bronx, New York, USA
Division of General Internal Medicine, Yeshiva University Albert Einstein College of Medicine, Bronx, New York, USA.
BMJ Open. 2021 Apr 24;11(4):e047443. doi: 10.1136/bmjopen-2020-047443.
Current HIV guidelines recommend differentiated service delivery (DSD) models that allow for fewer health centre visits for clinically stable people living with HIV (PLHIV). Newly diagnosed PLHIV may require more intensive care early in their treatment course, yet frequent appointments can be burdensome to patients and health systems. Determining the optimal parameters for defining clinical stability and transitioning to less frequent appointments could decrease patient burden and health system costs. The objectives of this pilot study are to explore the feasibility and acceptability of (1) reducing the time to DSD from 12 to 6 months after antiretroviral therapy (ART) initiation,and (2) reducing the number of suppressed viral loads required to enter DSD from two to one.
The present study is a pilot, unblinded trial taking place in three health facilities in Kigali, Rwanda. Current Rwandan guidelines require PLHIV to be on ART for ≥12 months with two consecutive suppressed viral loads in order to transition to less frequent appointments. We will randomise 90 participants to one of three arms: entry into DSD at 6 months after one suppressed viral load (n=30), entry into DSD at 6 months after two suppressed viral loads (n=30) or current standard of care (n=30). We will measure feasibility and acceptability of this intervention; clinical outcomes include viral suppression at 12 months (primary outcome) and appointment attendance (secondary outcome).
This clinical trial was approved by the institutional review board of Albert Einstein College of Medicine and by the Rwanda National Ethics Committee. Findings will be disseminated through conferences and peer-reviewed publications, as well as meetings with stakeholders.
NCT04567693.
当前的艾滋病病毒指南推荐采用差异化服务提供(DSD)模式,以使临床症状稳定的艾滋病病毒感染者(PLHIV)减少到医疗中心就诊的次数。新诊断的PLHIV在治疗初期可能需要更强化的护理,但频繁预约对患者和医疗系统来说都可能是负担。确定定义临床稳定性并过渡到较少频率预约的最佳参数,可以减轻患者负担并降低医疗系统成本。这项试点研究的目的是探讨以下两点的可行性和可接受性:(1)将开始抗逆转录病毒治疗(ART)后进入DSD的时间从12个月缩短至6个月;(2)将进入DSD所需的病毒载量被抑制次数从两次减少至一次。
本研究是一项在卢旺达基加利的三个医疗机构进行的非盲法试点试验。卢旺达现行指南要求PLHIV接受抗逆转录病毒治疗≥12个月且连续两次病毒载量被抑制,以便过渡到较少频率的预约。我们将把90名参与者随机分为三组:在一次病毒载量被抑制后6个月进入DSD组(n = 30)、在两次病毒载量被抑制后6个月进入DSD组(n = 30)或现行标准治疗组(n = 30)。我们将评估该干预措施的可行性和可接受性;临床结局包括12个月时的病毒抑制情况(主要结局)和预约就诊情况(次要结局)。
这项临床试验已获得阿尔伯特·爱因斯坦医学院机构审查委员会和卢旺达国家伦理委员会的批准。研究结果将通过会议、同行评审出版物以及与利益相关者的会议进行传播。
NCT04567693。